The US Food and Drug Administration has approved the first targeted treatment for indolent systemic mastocytosis, a rare and chronic blood disorder that causes severe, lifelong symptoms for thousands of patients. The approval of avapritinib marks a paradigm shift, moving beyond symptom management to directly target the disease's root cause.
Indolent systemic mastocytosis (ISM) is characterized by the abnormal accumulation of mast cells, a type of white blood cell, in tissues throughout the body. This leads to a wide range of debilitating symptoms, including painful skin reactions, gastrointestinal distress, cognitive issues, and severe systemic reactions like anaphylaxis. For decades, treatment has relied on non-targeted anti-inflammatory medications to blunt symptoms, an approach often limited by inconsistent effectiveness and side effects. "For most patients, the medications that have been available to treat them aren't highly or consistently effective," explained Dr. Jason Gotlib, who led the pivotal clinical trial.
The breakthrough stems from targeting KIT D816V, a mutated protein that drives the uncontrolled growth of mast cells and is present in approximately 95% of ISM patients. Avapritinib is a precision therapy designed to selectively inhibit this mutated protein, disrupting the signaling pathways that lead to mast cell accumulation. The approval was based on the landmark PIONEER study, a double-blind, placebo-controlled trial involving 212 patients with moderate to severe ISM.
In the 24-week trial, patients receiving a once-daily 25 mg dose of avapritinib showed significantly greater improvement in total symptom scores and key biomarkers of mast cell burden compared to those on placebo. The therapy was notably well-tolerated, with most side effects, such as dizziness and flushing, being mild. Serious adverse reactions leading to treatment discontinuation occurred in less than 1% of patients.
The ongoing Part 3 of the PIONEER trial will evaluate the long-term safety and efficacy of avapritinib for up to five years, with all participants now receiving the active drug. For a patient community long burdened by ineffective options, this first targeted therapy offers a new standard of care and tangible hope for reclaiming daily function and quality of life. "To have a new therapy that can effectively manage a broad range of symptoms," said Gotlib, "gives patients with ISM a renewed sense of hope."